Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Previously Presented). A method for treating cellinhibiting necrosis in neuronal, Purkinje, hippocampal, pyramidal or glial cells, or treating a neurodegenerative disorder associated therewith with necrosis of said cells, comprising the inhibition of one or more intracellular administering an elastase enzymes within said cell by means of administration of a therapeutically effective amount of one or more elastase inhibiting agents in an amount sufficient to inhibit necrosis of said cells, wherein said elastase inhibitors are inhibiting agent is capable of entering said cellcells.

- 2 (Cancelled).
- 3 (Previously Presented). The method according to claim 1, wherein the one or more elastase inhibiting agents administered cause partial conversion of necrosis to apoptosis, and wherein said method further comprises administration of an anti-apoptotic agent.

4-17 (Cancelled).

18 (Previously Presented). A method for treating cell necrosis—or a neurodegenerative disorder associated therewith, comprising administering to a subject in need a therapeutically sub-effective amount of one or more elastase inhibiting agents in an amount sufficient to inhibit necrosis of said cells and cause partial conversion of necrosis to apoptosis, and wherein said method further comprises administration and a therapeutically effective amount of an anti-apoptotic agent, wherein said one or more amount of elastase inhibiting agents and said agent is less than the optimal amount for inhibiting necrosis when

<u>an</u> anti-apoptotic agent have a synergistic protective effect against necrosis on said cells is not used.

19 -20 (Cancelled).

21 (New). A method for inhibiting necrosis in neuronal, Purkinje, hippocampal, pyramidal or glial cells, or treating a neurodegenerative disorder associated with necrosis of said cells, comprising administering an elastase inhibiting agent in an amount sufficient to inhibit necrosis of said cells, wherein said elastase inhibiting agent is capable of entering said cells and inhibiting an enzyme acting in the cells undergoing necrosis.